Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentastarch (Fresenius Kabi)
- Development stage
- Unknown
- Lead developer
- Fresenius Kabi
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pentastarch (hydroxyethyl starch 200/0.5) is a synthetic colloid plasma volume expander derived from amylopectin. It is characterized by a mean molecular weight of 200,000 Daltons and a molar substitution of 0.5. The drug is administered intravenously to treat hypovolemia and hemorrhagic shock by increasing the colloid osmotic pressure of the blood, which facilitates the expansion of plasma volume. While effective for volume resuscitation, its use in critically ill patients, particularly those with severe sepsis, has been associated with an increased risk of renal failure and mortality, leading to significant clinical restrictions and the termination of several trials in these populations.
- Brand names
- HAES-sterilPentaspanPentafraction
- Other names
- hydroxyethyl starch 200/0.5HES 200/0.5pentastarch
Beyond the preview
Go deeper on pentastarch (Fresenius Kabi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentastarch (Fresenius Kabi).